Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
The development of macroaggregated albumin (MAA) in 1964 led to the first successful lung scans in human beings. The distribution of pulmonary arterial blood flow is usually demonstrated by the intravenous injection of radioactive particles.
Radionuclide lung imaging most commonly involves determination of pulmonary perfusion by embolizing a very small percentage of the pulmonary capillary/arteriolar network, as well as the assessment of ventilation using inert gas, or radiolabeled aerosols. This combined information comparing regional blood flow and regional ventilation allows more accurate assessment of pulmonary pathophysiology for the non-invasive evaluation of pulmonary embolism, differential lung function or other specifically directed clinical questions on lung pathology.
The combined performance of both a pulmonary perfusion and ventilation study increases both the diagnostic sensitivity and specificity of the procedure.
The recommended number of particles for a single injection (70 kg adult) is approximately 350 000: to prepare a dose of 350 000 particles but other than 93 MBq (2.5 mCi), please refer to the “Simplified Reconstitution Recommendations” below.
Simplified Reconstitution Recommendations
3 million particles
4 million particles
5 million particles
6 million particles
7 million particles
8 million particles
Kit for the Preparation of Technetium Tc 99m Albumin Aggregated Injection
Each kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Albumin Aggregated Injection for diagnostic use by intravenous injection. Available in kits containing 10 reaction vials.
The Albumin Human contained in the DRAXIMAGE® MAA kit was non-reactive when tested for Hepatitis-B Surface Antigen (HBsAg), antibodies to Human immunodeficiency Virus (HIV-1/HIV-2), antibody to Hepatitis C virus (anti-HCV) and Antigen to Human Immunodeficiency Virus (HIV-1). Each vial contains 4 to 8 million particles.
Tc 99m Albumin Aggregated Injection should not be administered to patients with severe pulmonary hypertension.
In patients with right-to-left heart shunts, additional risk may exist due to the rapid entry of aggregated albumin into the systemic circulation.
This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.